Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Prostate Cancer Metastatic × Pluvicto × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 21 Prostatic Diseases 2 Metastatic Castration-resistant Prostate Cancer 2 Urogenital Neoplasms 1 Thrombocytopenia 1 Renal Insufficiency 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer Metastatic 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Neoplasms by Site 1 Neoplasms 1 Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1 Male Urogenital Diseases 1 Glioma 1 Glioblastoma 1 Genital Neoplasms, Male 1 Genital Diseases, Male 1 Disease 1 Cytopenia 1 Astrocytoma 1 Anemia 1

Interventions

Androgen Antagonists 3 Radiosurgery 2 pembrolizumab 1 fludrocortisone acetate 1 enzalutamide 1 darolutamide 1 cabazitaxel 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Prednisone 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Docetaxel 1 Dexamethasone 1 Carboplatin 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡